$AFMD spinout with novel #AML patient selection assay for #AMV564, Amphivena's lead therapeutic in hematology, presented at the 62nd #ASH2020 https://t.co/TjQ9HH6Hzj
$AFMD Affimed hidden news of the day:
premix 'in-situ CAR'-NK seem to work in "... CD30 expressing lymphomas..." with "... the first patient has completed the first four-week cycle without noteworthy toxicity and has achieved a partial response ..." https://t.co/3ZH1pXjuIK
$AFMD Affimed hidden news of the day:
premix 'in-situ CAR'-NK seem to work in "... CD30 expressing lymphomas..." with "... the first patient has completed the first four-week cycle without noteworthy toxicity and has achieved a partial response ..." https://t.co/3ZH1pXjuIK